Affinity Asset Advisors LLC Acquires 325,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Affinity Asset Advisors LLC lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 65.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 824,328 shares of the company's stock after buying an additional 325,908 shares during the quarter. Spyre Therapeutics makes up 2.6% of Affinity Asset Advisors LLC's investment portfolio, making the stock its 10th largest holding. Affinity Asset Advisors LLC owned approximately 1.60% of Spyre Therapeutics worth $19,190,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of Spyre Therapeutics by 16.7% in the 4th quarter. Barclays PLC now owns 123,071 shares of the company's stock valued at $2,866,000 after buying an additional 17,604 shares during the period. F M Investments LLC purchased a new stake in shares of Spyre Therapeutics in the 4th quarter worth about $1,136,000. Legal & General Group Plc grew its holdings in Spyre Therapeutics by 14.8% during the 4th quarter. Legal & General Group Plc now owns 37,490 shares of the company's stock valued at $873,000 after buying an additional 4,824 shares during the last quarter. FMR LLC lifted its holdings in Spyre Therapeutics by 15.4% in the 4th quarter. FMR LLC now owns 8,801,266 shares of the company's stock valued at $204,893,000 after purchasing an additional 1,177,385 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Spyre Therapeutics by 38.8% in the 4th quarter. Wells Fargo & Company MN now owns 24,718 shares of the company's stock worth $575,000 after acquiring an additional 6,908 shares during the period. Institutional investors and hedge funds own 80.39% of the company's stock.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics stock traded up $0.25 on Friday, reaching $12.67. 740,114 shares of the company were exchanged, compared to its average volume of 591,762. Spyre Therapeutics, Inc. has a 1-year low of $10.91 and a 1-year high of $40.49. The firm has a market cap of $763.70 million, a price-to-earnings ratio of -1.70 and a beta of 3.05. The company's 50-day moving average is $17.44 and its two-hundred day moving average is $23.75.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08. As a group, sell-side analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on SYRE. Leerink Partners began coverage on shares of Spyre Therapeutics in a research note on Tuesday, April 8th. They set an "outperform" rating and a $45.00 price objective for the company. Leerink Partnrs raised shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 8th. Wolfe Research began coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price objective for the company. Wedbush reiterated an "outperform" rating and issued a $65.00 target price on shares of Spyre Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Spyre Therapeutics has an average rating of "Buy" and a consensus target price of $49.57.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).